A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
Columbia University
University of Nebraska
H. Lee Moffitt Cancer Center and Research Institute
UNICANCER
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
Roswell Park Cancer Institute
University of Arizona
M.D. Anderson Cancer Center
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Masonic Cancer Center, University of Minnesota
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OHSU Knight Cancer Institute
Dana-Farber Cancer Institute
Newcastle-upon-Tyne Hospitals NHS Trust
French Innovative Leukemia Organisation
Memorial Sloan Kettering Cancer Center
Vanderbilt-Ingram Cancer Center
Istituto Clinico Humanitas
Memorial Sloan Kettering Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Northwestern University
Northwestern University
Swiss Cancer Institute
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Case Comprehensive Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Virginia Commonwealth University